Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 5Specimen Handling 4Magnetic Resonance Spectroscopy 4Biopsy 4Nivolumab 3sodium-iodide symporter 2fludarabine 2cemiplimab 2X-Rays 2Whole-Body Irradiation 2Stem Cell Transplantation 2Photons 2Mycophenolic Acid 2Immunoglobulin G 2Disulfides 2Cyclosporine 210-propargyl-10-deazaaminopterin 2treosulfan 1talimogene laherparepvec 1sargramostim 1ruxolitinib 1pembrolizumab 1fludarabine phosphate 1entrectinib 1duvelisib 1ceritinib 1belinostat 1alectinib 1Vincristine 1Vinblastine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large-Cell, Anaplastic × Abatacept × 90 days × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡